Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2020 April;72(2) > Minerva Urologica e Nefrologica 2020 April;72(2):173-86



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


REVIEW   Free accessfree

Minerva Urologica e Nefrologica 2020 April;72(2):173-86

DOI: 10.23736/S0393-2249.19.03323-X


lingua: Inglese

The management of stuttering priapism

Giovanni LIGUORI 1 , Michele RIZZO 1, Riccardo BOSCHIAN 1, Tommaso CAI 2, Alessandro PALMIERI 3, Stefano BUCCI 1, Nicola PAVAN 1, Francesco CLAPS 1, Matteo BOLTRI 1, Michele BERTOLOTTO 4, Carlo TROMBETTA 1

1 Department of Urology, University of Trieste, Trieste, Italy; 2 Department of Urology, Santa Chiara Hospital, Trento, Italy; 3 Department of Urology, Federico II University, Naples, Italy; 4 Department of Radiology, University of Trieste, Trieste, Italy

INTRODUCTION: Stuttering priapism is a variation of ischemic priapism, generally transient and self-limiting, occurring during sleep and lasting less than 3-4 hours. It may progress to episodes of complete ischemic priapism in approximately one third of cases, necessitating emergent intervention.
EVIDENCE ACQUISITION: This review aims to provide an up-to-date picture of the pathophysiology and management of stuttering priapism. A search using Medline and EMBASE for relevant publications using the terms “priapism”, “stuttering”, “diagnosis”, “treatment”, “fibrosis”, was performed.
EVIDENCE SYNTHESIS: Stuttering priapism shares its etiologies with ischemic priapism and a large number of diseases or clinical situations have risk association for developing the disorder. The most common causes are sickle cell disease or other hematologic and coagulative dyscrasias especially in children. In the adult population, idiopathic priapism occurring without any discernible cause is considered to be the most common form in adults. The medical management of priapism represents a therapeutic challenge to urologists. Unfortunately, although numerous medical treatment options have been reported, the majority are through small trials or anecdotal reports. Understanding the underlying pathophysiology and understanding the current and emerging future agents and therapeutic options are mandatory in order to provide the best solution for each patient.
CONCLUSIONS: The goal of management of priapism is to achieve detumescence of the persistent erection in order to preserve erectile function. To achieve successful management, urologists should address this emergency clinical condition. In the present article, we review the diagnosis and clinical management of the three types of priapism.

KEY WORDS: Priapism; Therapeutics; Review

inizio pagina